Abstract
Identified in 1993 and located on chromosome 4p16.3, the human HD gene (also called IT15) contains 67 exons and spans more than 200 kb. It harbors meiotically unstable CAG trinucleotide or polyglutamine repeats (cytosine, adenine, guanine) in its exon 1, which encode the very large 350 kDa huntingtin protein (Htt). Htt consists of about 3100 amino acids and undergoes extensive posttranslational modifications (Fig. 9.1) (Andrew et al. 1993; Atkin and Paulson 2014; Borrell-Pagès et al. 2006; Brundin et al. 2010; Cattaneo et al. 2005; Davies et al. 2007; Duyao et al. 1993; Finkbeiner and Mitra 2008; Imarisio et al. 2008; Labbadia and Morimoto 2013; Li and Conforti 2013; Li and Li 2011; Margolis and Ross 2003; Myers et al. 1993; Ortega et al. 2007; Paul 2008; Renner and Melki 2014; Schulte and Littleton 2011; The Huntington’s disease Collaborative Research Group 1993; Vonsattel 2008; Walker 2007a, b).
Keywords
- Neuronal Aggregation
- Neuronal Intranuclear Inclusion
- Affected Nerve Cell
- Polyglutamine Protein
- Intraneuronal Aggregation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr A, Squitieri S, Lin B, Kalchman MA, Graham RK, Hayden MR (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4:398–403
Atkin G, Paulson H (2014) Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci 7:63
Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA (1998) Intranuclear neuronal inclusions in Huntington’s disease anddentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387–397
Borrell-Pagès M, Zala D, Humbert S, Saudou F (2006) Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 63:2642–2660
Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11:301–307
Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci 6:919–939
Davies JE, Sarkar S, Rubinsztein DC (2007) The ubiquitin proteasome system in Huntingtion’s disease and the spinocerebellar ataxias. BMC Biochem 8(Suppl):1–8
De Vos KJ, Grierson AJ, Ackerley S, Miller CCJ (2008) Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 31:1151–1173
Difiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993
Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, Gray J, Coneally P, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini A, Falck A, Koroshetz W, Sax D, Bird E, Vonsattel J, Bonilla E, Alvir J, Bickham Conde J, Cha JH, Dure L, Gomez F, Ramos M, Sanchez-Ramos J, Snodgrass S, de Young M, Wexler N, Moscowitz C, Penchaszadeh G, MacFarlane H, Anderson M, Jenkins B, Srinidhi J, Barnes G, Gusella JMM (1993) Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 4:387–392
Finkbeiner S, Mitra S (2008) The ubiquitin-proteasome pathway in Huntington’s disease. ScientificWorldJournal 8:421–433
Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 27:2803–2820
Gourfinkel-An I, Cancel G, Duyckaerts C, Faucheux B, Hauw JJ, Trottier Y, Brice A, Agid Y, Hirsch EC (1998) Neuronal distribution of intranuclear inclusions in Huntington’s disease with adult onset. Neuroreport 9:1823–1826
Gunawardena S, Goldstein LSB (2005) Polyglutamine diseases and transport problems. Arch Neurol 62:46–51
Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington’s disease: relationship to neuropathology. J Neurosci 19:2522–2534
Hoche F, Seidel K, Brunt ER, Auburger G, Schöls L, Bürk K, de Vos RA, den Dunnen W, Bechmann I, Egensperger R, Van Broeckhoven C, Gierga K, Deller T, Rüb U (2008) Involvement of the auditory brainstem system in spinocerebellar ataxia type 2 (SCA2), type 3 (SCA3) and type 7 (SCA7). Neuropathol Appl Neurobiol 34:479–491
Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, Krishna G, Davies JE, Ttofi E, Underwood BR, Rubinsztein DC (2008) Huntington’s disease: from pathology and genetics to potential therapies. Biochem J 412:191–209
Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70:532–540
Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 46:842–849
Kuusisto E, Salminen A, Alafuzoff I (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12:2085–2090
Kuusisto E, Kauppinen T, Alafuzoff I (2008) Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 34:169–180
Labbadia J, Morimoto RI (2013) Huntington’s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378–385
Leak RK (2014) Heat shock proteins in neurodegenerative disorders and aging. J Cell Commun Signal 8:293–310
Li JY, Conforti L (2013) Axonopathy in Huntington’s disease. Exp Neurol 246:62–71
Li XJ, Li S (2011) Proteasomal dysfunction in aging and Huntington disease. Neurobiol Dis 43:4–8
Maat-Schieman ML, Dorsman JC, Smoor MA, Siesling S, van Duinen SG, Verschuuren JJ, den Dunnen JT, van Ommen GJ, Roos RA (1999) Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol 58:129–137
Maat-Schieman M, Roos R, Losekoot M, Dorsman J, Welling-Graafland C, Hegeman-Kleinn I, Broeyer F, Breuning M, van Duinen S (2007) Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington’s disease. Brain Pathol 17:31–37
Margolis RL, Ross CA (2003) Diagnosis of Huntington disease. Clin Chem 49:1726–1732
Millecamps S, Julien JP (2013) Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 14:161–176
Oliveira JMA (2010) Nature and cause of mitochondrial dysfunction in Huntington’s disease: focusing on huntingtin and the striatum. J Neurochem 114:1–12
Ortega Z, Díaz-Hernández M, Lucas JJ (2007) Is the ubiquitin-proteasome system impaired in Huntington’s disease? Cell Mol Life Sci 64:2245–2257
Pandey M, Mohanakumar KP, Usha R (2010) Mitochondrial functional alterations in relation to pathophysiology of Huntington’s disease. J Bioenerg Biomembr 42:217–226
Paul S (2008) Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 3:1172–1184
Renner M, Melki R (2014) Protein aggregation and prionopathies. Pathol Biol 62:162–168
Rüb U, Del Tredici K, Schultz C, Büttner-Ennever JA, Braak H (2001) The premotor region essential for rapid vertical eye movements shows early involvement in Alzheimer’s disease-related cytoskeletal pathology. Vision Res 41:2149–2156
Rüb U, Brunt ER, Deller T (2008a) New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 21:111–116
Rüb U, Hoche F, Brunt ER, Heinsen H, Seidel K, Del Turco D, Paulson HL, Bohl J, von Gall C, Vonsattel JP, Korf HW, den Dunnen WF (2013a) Degeneration of the cerebellum in Huntington’s disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol 23:165–177
Rüb U, Schöls L, Paulson H, Auburger G, Kermer P, Jen JC, Seidel K, Korf HW, Deller T (2013b) Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol 104:38–66
Rüb U, Hentschel M, Stratmann K, Brunt E, Heinsen H, Seidel K, Bouzrou M, Auburger G, Paulson H, Vonsattel JP, Lange H, Korf HW, den Dunnen W (2014a) Huntington’s disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem. Brain Pathol 24:247–260
Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, Difiglia M (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58:165–173
Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet 384:545–555
Schulte J, Littleton JT (2011) The biological function of the Huntingtin protein and its relevance to Huntington’s Disease pathology. Curr Trends Neurol 5:65–78
Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068
Seidel K, Den Dunnen WF, Schultz C, Paulson H, Frank S, de Vos RA, Brunt ER, Deller T, Kampinga HH, Rüb U (2010) Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 120:449–460
Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rüb U (2012) Brain pathology of spinocerebellar ataxias. Acta Neuropathol 124:1–21
Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM (1999) Huntington’s disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156:92–99
The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983
Trottier Y, Lutz Y, Stevanin G, Imbert DD, Cancel G, Saudou F, Weber C, David G, Tora L, Agid Y, Brice A, Mandel JL (1995) Polyglutamine expansion as a pathological epitope in Huntington’s disease and four dominant cerebellar ataxias. Nature 378:403–406
Valera AG, Diaz-Hernandez M, Hernandez F, Ortega Z, Lucas JJ (2005) The ubiquitin-proteasome system in Huntington’s disease. Neuroscientist 11:583–594
Vonsattel JP (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:55–69
Walker FO (2007a) Huntington’s disease. Semin Neurol 27:143–150
Walker FO (2007b) Huntington’s disease. Lancet 369:218–228
Whitney ER, Kemper TL, Rosene DL, Bauman ML, Blatt GJ (2008) Calbindin-D28k is a more reliable marker of human Purkinje cells than standard Nissl stains: a stereological experiment. J Neurosci Methods 168:42–47
Wooten MW, Hu X, Babu JR, Seibenhener ML, Geetha T, Paine MG, Wooten MC (2006) Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62’s role in neurodegenerative disease. J Biomed Biotechnol 2006:1–12. Article ID 62079
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rüb, U., Vonsattel, J.P.G., Heinsen, H., Korf, HW. (2015). The Disease Protein Huntingtin and Neuronal Protein Aggregations in Huntington’s Disease (HD). In: The Neuropathology of Huntington’s Disease: Classical Findings, Recent Developments and Correlation to Functional Neuroanatomy. Advances in Anatomy, Embryology and Cell Biology, vol 217. Springer, Cham. https://doi.org/10.1007/978-3-319-19285-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-19285-7_9
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-19284-0
Online ISBN: 978-3-319-19285-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)